Brief: Lexeo Therapeutics Announces Positive Interim Data For Lx1001, First-Ever Gene Therapy To Impact The Underlying Genetic Cause Of Apoe4-Associated Alzheimer’S Disease, At The Clinical Trials On Alzheimer’S Disease (Ctad) Conference
30/10/2024 10:53
Oct 30 (Reuters) - Lexeo Therapeutics Inc LXEO.O :
* LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FOR
LX1001,
FIRST-EVER GENE THERAPY TO IMPACT THE UNDERLYING GENETIC CAUSE
OF APOE4-ASSOCIATED ALZHEIMER’S DISEASE, AT THE CLINICAL TRIALS
ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
* LEXEO THERAPEUTICS INC - LX1001 WELL TOLERATED WITH NO
REPORTS
OF ARIA
* LEXEO THERAPEUTICS - SEES FURTHER LX1001 DEVELOPMENT
PLANS IN
2025
Source text: ID:nGNX8tGhr4
Further company coverage: LXEO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease